Skip to main content
Voyageur Pharmaceuticals Ltd. logo

Voyageur Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · VM ISIN · CA92918C1014 TSXV Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2022-05-27 Capital/Financing Update
Country CA Canada
Listing TSXV VM

About Voyageur Pharmaceuticals Ltd.

https://voyageurpharmaceuticals.ca/

Voyageur Pharmaceuticals Ltd. develops and supplies contrast media products for medical imaging, including CT scans and fluoroscopy. The company operates using a vertically integrated "Earth to Bottle" strategy, controlling the entire supply chain from raw mineral acquisition to finished pharmaceutical product. Voyageur owns a significant, high-purity barium sulfate resource, positioning it as a secure and sustainable supplier of pharmaceutical-grade barium sulfate, the active ingredient in its commercialized contrast agents (e.g., SmoothX® and SmoothHD® series). This vertical control aims to ensure supply security and cost competitiveness, primarily targeting the North American market. The company is also actively developing iodine-based contrast media and V-Gas® Effervescent Granules to expand its portfolio of diagnostic imaging solutions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a news release announcing a proposed private placement by Voyageur Pharmaceuticals Ltd. It details the terms of the offering, including the number of units, pricing, warrants, use of proceeds, and regulatory approvals required. There is no financial statement or detailed financial analysis present, nor is this a report or transcript. The content clearly relates to a capital raising activity, specifically a private placement financing. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing terms, not just an announcement of a report or a brief notice.
2022-05-27 English
Material change report - English.pdf
Regulatory Filings
2022-05-20 English
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a news release from Voyageur Pharmaceuticals announcing progress on product development, regulatory submissions to the FDA, manufacturing plans, and business strategy. It discusses milestones, future plans, and forward-looking statements but does not contain financial statements, detailed financial results, or regulatory filings such as annual or quarterly reports. It is not a transcript, audit report, or governance document. The content is primarily an operational and commercial update aimed at investors and the public. Given the nature of the document as a news release announcing business progress and milestones rather than a formal financial or regulatory filing, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other specific categories.
2022-05-19 English
News release - English.pdf
Regulatory Filings
2022-05-11 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification form titled 'FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE' signed by the CFO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended February 28, 2022. The text explicitly states it is a certification of interim filings, not the filings themselves. The document length is short (2994 characters), and it primarily contains an officer's attestation rather than substantive financial data or analysis. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report itself (IR).
2022-04-30 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification form titled 'FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE' signed by the CEO certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended February 28, 2022. It explicitly states it is a certification of interim filings, not the filings themselves. The document contains no actual financial data or detailed financial statements, only a certification statement. According to the CERTIFICATION RULE, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is short (3033 characters), consistent with a certification letter rather than a full report.
2022-04-30 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.